Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.49 |
| ▸ | RAF1 | P04049 | 6/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.43 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28406044 | 1.00 | GSK3B (0.57) | GSK3BNOTUMMAPK13MAPK12MAPK11 | |
| SCHEMBL528246 | 0.90 | MEN1 (0.46) | GSK3BKDM4EKMT2AHPGDSALDH1A1 | |
| SCHEMBL2839049 | 0.89 | GSK3B (0.51) | GSK3BNOTUMMAPK13MAPK12MAPK11 | |
| SCHEMBL2834587 | 0.87 | HPGDS (0.58) | GSK3BNOTUMMAPK13MAPK12MAPK11 | |
| SCHEMBL4847155 | 0.86 | HPGDS (0.43) | GSK3BMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7139559 | 0.86 | HPGDS (0.43) | GSK3BMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL17279780 | 0.82 | MEN1 (0.43) | GSK3BKDM4EKMT2ACDC7ALDH1A1 | |
| SCHEMBL8311417 | 0.82 | GCGR (0.51) | GSK3BMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6268973 | 0.82 | NPY5R (0.50) | KDM4ENPY5RHPGDSALDH1A1MAPT | |
| Pyrrole SCHEMBL28081576 | 0.81 | MTOR (0.41) | GSK3BKDM4EKMT2AHPGDSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-20130040983-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION | 2013-02-14 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085269-A1 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011038261-A1 | HETEROCYCLIC KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038261-A1 | HETEROCYCLIC KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | DEAN DAVID K | 2007-06-14 | — | — | US | disclosed |
| US-7199137-B2 | Imidazole derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2007-04-03 | — | — | US | disclosed |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| CN-1471523-A | Imidazole derivatives as Raf kinase inhibitors | ʷ | 2004-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040983-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GSK3B 355/4885NOTUM 3570/4885MAPK13 142/4885 |
| US-20070135433-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GSK3B 449/4885NOTUM 4022/4885MAPK13 80/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | GSK3B 1075/4885NOTUM 4669/4885MAPK13 178/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | GSK3B 745/4885NOTUM 2825/4885MAPK13 197/4885 |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | GSK3B 427/4885NOTUM 4494/4885MAPK13 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.